Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia

DNA and Cell Biology

Volumn 31, Issue 5, 2012, Pages 777-782

  Isin, Mustafa ^a   Yenerel, Mustafa ^b   Aktan, Melih ^b   Buyru, Nur ^c   Dalay, Nejat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN;

ARTICLE; B CELL LYMPHOMA 6 GENE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN HOMOLOG OF MURINE DOUBLE MINUTE 2 GENE; HYBRIDIZATION; MUTATIONAL ANALYSIS; P14 ALTERNATING READING FRAME GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SPLICING DEFECT; TUMOR SUPPRESSOR GENE; ZINC FINGER AND BTB DOMAIN CONTAINING 7A GENE;

CASE-CONTROL STUDIES; DNA; FEMALE; FIBRONECTINS; GENOTYPE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE;

EID: 84861401307     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1314     Document Type: Article

References (52)

1. Aguilera, A.S., et al. (2002). p14ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood 99, 1411-1418.
2. Astier, A.L., et al. (2003). Temporal gene expression profile of human procursor B leukemia cells induced by adhesion receptor:identification of pathways regulating B-cell survival. Blood 101, 1118-1127. (Pubitemid 36139387)
3. Barna, M., et al. (2000). Plzf regulates limb and axial skeletal patterning. Nat Genet 25, 166-172. (Pubitemid 30394986)
4. Binet, J.L., et al. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206. (Pubitemid 11064396)
5. Buyru, N., et al. (2003). P53 gene mutations are rare in human papillomavirus-associated colon cancer. Oncol Rep 10, 2089-2092.
6. Chao, C., et al. (2003). Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem 278, 41028-41033. (Pubitemid 37280926)
7. Chiorazzi, N., et al. (2005). Chronic lymphocytic leukemia. N Engl J Med 352, 804-815.
8. Costoya, J.A., et al. (2004). Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet 36, 653-659. (Pubitemid 38715996)
9. Dameshek, W. (1967). Chronic lymphocytic leukemia an accumulative disease of immunologically incompetent lymphocytes. Blood 29, 566-584.
10. Damle, R.N., et al. (2002). B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99, 4087-4093. (Pubitemid 35332051)
11. D'Arena, G., et al. (2007). Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol 82, 787-791.
12. De Wever, O., et al. (2011). Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts. Int J Oncol 39, 393-400.
13. Deb, S.P. (2003). Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 1, 1009-1016. (Pubitemid 38044976)
14. Efeyan, A., and Serrano, M. (2007). p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6, 1006-1010. (Pubitemid 46708570)
15. Faber, A.C., and Chiles, T.C. (2006). Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling. Int J Oncol 29, 1561-1566.
16. Ghosh, A., et al. (2010a). Proapoptotic fibronectin fragment induces the degradation of ubiquitinated proteasomes in periodental ligament cells. J Periodental Res. 45, 481-487.
17. Ghosh, A., et al. (2010b). Anoikis trggers Mdm2-dependent p53 degradation. Mol Cell Biochem 343, 201-209.
18. Fais, F., et al. (1998). Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102, 1515-1525. (Pubitemid 28492218)
19. Haidar, M.A., et al. (1997). Expression profiles of MDM2 proteins in chronic lymphocytic leukemia and their clinical relevance. Am J Hematol 54, 189-195. (Pubitemid 27148256)
20. Hamblin, T.J. (2007). Prognostic markers in chronic lympocytic leukaemia. Best Pract Res Clin Haematol 20, 455-468. (Pubitemid 47250493)
21. Haupt, Y., et al. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299. (Pubitemid 27220766)
22. He, X., et al. (2005). The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 433, 826-833. (Pubitemid 40314886)
23. Jemal, A., et al. (2006). Cancer statistics 2006. CA Cancer J Clin 56, 106-130.
24. Kamijo, T., et al. (1998). Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95, 8292-8297. (Pubitemid 28326106)
25. Keating, M.J., et al. (2005). Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23, 4079-4088. (Pubitemid 46211313)
26. Konikova, E., and Kusenda, J. (2003). Altered expression of p53 and MDM2 proteins in hematological malignancies. Neoplasma 50, 30-40.
27. Lane, D.P., and Fischer, P.M. (2004). Turning the key on p53.1. Nature 427, 789-790.
28. Maeda, T., et al. (2005a). Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433, 278-285.
29. Maeda, T., et al. (2005b). The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res 65, 8575-8578. (Pubitemid 41377337)
30. Margalit, O., et al. (2006). BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. Blood 107, 1599-1607. (Pubitemid 43242399)
31. Messmer, B.T., et al. (2005). In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115, 755-764. (Pubitemid 40322252)
32. Mills, A.A. (2005). p53: link to the past, bridge to the future. Genes Dev 19, 2091-2099. (Pubitemid 41330311)
33. Moreno, C., and Montserrat, E. (2008). New prognostic markers in chronic lymphocytic leukemia. Blood Rev 22, 211-219.
34. Murray-Zmijewski, F., et al. (2008). A complex barcode underlies the heterogeneous response of p53 to stress. Nature Rev Mol Cell Biol 9, 702-712.
35. Phan, R.T., and Dalla-Favera, R. (2004). The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635-639. (Pubitemid 39626271)
36. Poliseno, L., et al. (2008). The proto-oncogene LRF is under posttranscriptional control of MiR-20a: implications for senescence. PLoS One 3, e2542.
37. Rai, K.R., et al. (1975). Clinical staging of chronic lymphocytic leukemia. Blood 46, 219-234.
38. Ramos, C.E., et al. (1995). Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk Lymphoma 17, 13-18.
39. Richardson, S.J., et al. (2006). ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107, 3584-3592.
40. Rosenwald, A., et al. (2001). Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194, 1639-1647. (Pubitemid 33126814)
41. Sherr, C.J. (2006). Divorcing Arf and p53: an unsettled case. Nature 6, 663-673. (Pubitemid 44285999)
42. Starostik, P., et al. (1998). Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 58, 4552-4557. (Pubitemid 28480612)
43. Stevenson, F.K., and Caligaris-Cappio, F. (2004). Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 103, 4389-4395. (Pubitemid 38745961)
44. Stilgenbauer, S., et al. (2002). Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course. Leukemia 16, 993-1007. (Pubitemid 34618838)
45. Unger, T., et al. (1999a). Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 18, 3205-3212. (Pubitemid 29286965)
46. Unger, T., et al. (1999b). Critical role for Ser20 of human p53 in the negative regulation of p53 by MDM-2. EMBO J 18, 1805-1814. (Pubitemid 29158524)
47. Watanabe, T., et al. (1994). The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84, 3158-3165.
48. Xu, W., et al. (2008). Prognostic significance of p53 and ATM gene deletion in patients with chronic lymphocytic leukemia. Zhonghua Xue Ye Xue Za Zhi 29, 450-453.
49. Yap, D.B.S., et al. (1999). Mdm2: a bridge over the two tumor suppressors, p53 and Rb. Oncogene 18, 7681-7689. (Pubitemid 30052695)
50. Ye, B.H., et al. (1997). The BCL-6 proto-oncogene controls germinal-centre formation and Th2- type inflammation. Nat Genet 16, 161-170.
51. Zainuddin, N., et al. (2011). TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 35, 272-274.
52. Zenz, T., et al. (2008). Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 7, 3810-3814.